Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma – The Changing Tides
Abdul Rehman Khan, Xuyong Wei, Xiao Xu
Journal of Hepatocellular Carcinoma (2021) Vol. Volume 8, pp. 1089-1115
Open Access | Times Cited: 76

Showing 1-25 of 76 citing articles:

Correlation and efficacy of TACE combined with lenvatinib plus PD‐1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features
Xinhua Zou, Qingyu Xu, Ran You, et al.
Cancer Medicine (2023) Vol. 12, Iss. 10, pp. 11315-11333
Open Access | Times Cited: 22
Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
Jeayeon Park, Yun Bin Lee, Yunmi Ko, et al.
Journal of Liver Cancer (2024) Vol. 24, Iss. 1, pp. 81-91
Open Access | Times Cited: 4
The Current and Prospective Adjuvant Therapies for Hepatocellular Carcinoma
Jeng‐Shiun Du, Shih‐Hsien Hsu, Shen‐Nien Wang
Cancers (2024) Vol. 16, Iss. 7, pp. 1422-1422
Open Access | Times Cited: 4
Efficacy and safety of neoadjuvant therapy for hepatocellular carcinoma with portal vein thrombosis: A meta‑analysis
Wangyi Xuan, Xiao Ming Zhang, Yingying Fang, et al.
Oncology Letters (2025) Vol. 29, Iss. 3
Open Access
Fully Covered Stent-TIPS for Advanced HCC Patients with Portal Vein Tumor Thrombus-Related Severe Symptomatic Portal Hypertension
Zechuan Liu, Tianshi Lyu, Jinming Yang, et al.
Journal of Hepatocellular Carcinoma (2025) Vol. Volume 12, pp. 29-41
Open Access
Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus
Xiaowei Li, Kunkun Cao, Zhigang Fu, et al.
Journal of Hepatocellular Carcinoma (2025) Vol. Volume 12, pp. 169-182
Open Access
Metastatic papillary thyroid carcinoma with internal jugular vein tumor thrombus - A case report and review of the literature
Adnan Zaina, Edmond Sabo, Sameer Kassem
Frontiers in Endocrinology (2025) Vol. 16
Open Access
Efficacy and safety of hepatic arterial infusion chemotherapy followed by transarterial embolization for hepatocellular carcinoma
Jun Yang, Shen Zhang, Yu Yin, et al.
Tumori Journal (2025)
Closed Access
Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?
Arvinder S. Soin, Mickaël Lesurtel, Prashant Bhangui, et al.
Journal of Hepatology (2023) Vol. 78, Iss. 6, pp. 1124-1129
Open Access | Times Cited: 12
Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
Yue Hu, Min Zhou, Jing Tang, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 20, pp. 4088-4097
Closed Access | Times Cited: 12
Mechanisms of portal vein tumour thrombus formation and development in patients with hepatocellular carcinoma
Zhenli Li, Mingda Zhao, Xingshun Qi, et al.
Journal of Cellular and Molecular Medicine (2023) Vol. 27, Iss. 15, pp. 2103-2111
Open Access | Times Cited: 11
Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus
Hongxiao Wu, Xiaoyan Ding, Yawen Xu, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 8, pp. 843-854
Open Access | Times Cited: 4
Low Psoas-Muscle index is associated with decreased survival in hepatocellular carcinoma treated with transarterial chemoembolization
Jin-Xing Zhang, Hai‐Tao Yan, Ding Ye, et al.
Annals of Medicine (2022) Vol. 54, Iss. 1, pp. 1562-1569
Open Access | Times Cited: 18
Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
Xinhua Zou, Qingyu Xu, Ran You, et al.
Advances in Therapy (2023) Vol. 40, Iss. 4, pp. 1686-1704
Closed Access | Times Cited: 10
A classification model for resectability in hepatocellular carcinoma patients
Ikuo Nakamura, Tomoaki Yoh, Takashi Nishimura, et al.
Hepatology Research (2024)
Open Access | Times Cited: 3
Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review
Zunyi Zhang, Erlei Zhang
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
Shuqun Li, Junyi Wu, Jiayi Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Neoadjuvant-Based Triple Therapy for Hepatocellular Carcinoma with Type I/II Portal Vein Tumor Thrombosis
Guimin Hou, Feng Zhang, Xielin Feng, et al.
Journal of Hepatocellular Carcinoma (2024) Vol. Volume 11, pp. 1581-1595
Open Access | Times Cited: 2
A Real-World Comparative Analysis of Atezolizumab Plus Bevacizumab and Transarterial Chemoembolization Plus Radiotherapy in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis
Soon Kyu Lee, Jung Hyun Kwon, Sung Won Lee, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4423-4423
Open Access | Times Cited: 6
A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms
Mayu Kobayashi, Hideo Wada, Shunsuke Fukui, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 22, pp. 5352-5352
Open Access | Times Cited: 14
Machine Learning-Based Development of Nomogram for Hepatocellular Carcinoma to Predict Acute Liver Function Deterioration After Drug-Eluting Beads Transarterial Chemoembolization
Jie Li, Yuyuan Zhang, Heqing Ye, et al.
Academic Radiology (2023) Vol. 30, pp. S40-S52
Open Access | Times Cited: 5
Chemoembolization as first-line treatment for hepatocellular carcinoma invading segmental portal vein with tumour burden limited to a monosegmental level
Hyeonseung Hwang, Jin Hyoung Kim, Eunbyeol Ko, et al.
British Journal of Radiology (2024) Vol. 97, Iss. 1157, pp. 1038-1043
Closed Access | Times Cited: 1
The current and prospective adjuvant therapies for hepatocel-lular carcinoma
Jeng‐Shiun Du, Shih‐Hsien Hsu, Shen-Nien Wang
(2024)
Open Access | Times Cited: 1
Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review
Rahmad Mulyadi, Irsan Hasan, Prijo Sidipratomo, et al.
Journal of the Egyptian National Cancer Institute (2024) Vol. 36, Iss. 1
Open Access | Times Cited: 1
Tumor burden score as a prognostic factor in patients with intermediate and locally advanced hepatocellular carcinoma undergoing liver resection: an attempt to extend resectability criteria
K. Nandy, Shraddha Patkar, Gurudutt Varty, et al.
HPB (2024) Vol. 26, Iss. 9, pp. 1180-1189
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top